Previous clinical studies have shown inconsistent results regarding the effect of erythropoietin in STsegment elevation myocardial infarction (STEMI). This study investigated whether directed intracoronary infusion of darbepoetin-α into ischemic myocardium before reperfusion would reduce infarct size or post-infarct remodeling in STEMI patients.
T imely myocardial reperfusion using thrombolysis or percutaneous coronary intervention (PCI) is the most optimal treatment for ST-segment elevation myocardial infarction (STEMI). However, reperfusion itself may also cause lethal myocardial injury and contribute to left ventricle (LV) function, infarct size, and adverse outcomes. 1) A number of pharmacological treatments have been shown reducing reperfusion injury in the preclinical studies, but the results of clinical studies have been largely disappointing. [2] [3] [4] Preclinical studies have suggested that administration of erythropoietin (EPO) reduces infarct size and improves ventricular function. [5] [6] [7] However, the efficacy of EPO in reducing myocardial injury in patients with acute myocardial infarction has been inconsistent in clinical studies. [8] [9] [10] [11] [12] The discrepancies in the results of human trials have been attributed to differences in the dosage, timing, and route of administration of EPO across the studies.
Darbepoetin-α is an erythropoiesis-stimulating protein with a threefold longer half-life than recombinant human EPO (r-HuEPO). 13) Clinical studies in patients with chronic kidney disease have shown darbepoetin-α to be equivalent to the synthetic form of r-HuEPO in terms of efficacy and safety. 14) Medications that are administered intravenously may not be delivered to the coronary circulation because of thrombotic occlusion of the coronary artery in the setting of STEMI. Therefore, the intracoronary administration of medications has been used to overcome the limitations of intravenous delivery in patients with STEMI. 15) However, the efficacy and safety of directed intracoronary infusion of darbepoetin-α into ischemic myocardium before reperfusion have not been tested in the setting of primary PCI.
In this study, we investigated whether the directed intracoronary administration of darbepoetin-α immediately before reperfusion could reduce infarct size or post-infarct remodeling in patients with STEMI.
Methods

Study design and population:
This was a single-center, prospective, randomized, single-blind, two-arm, controlled, phase 2 trial with blind evaluation of endpoints. Details of the trial design, methods, objectives, and study endpoints are described elsewhere (Clinical Trial Registration: http:// www. clinicaltrials. gov.
Unique identifier : NCT 01538771). 16) The trial was conducted in accordance with the Declaration of Helsinki (revised version, 2013) and relevant Korean laws. The institutional review board of Seoul National University Bundang Hospital approved this study. All the subjects provided written informed consent before enrollment.
All patients, regardless of sex, aged 18-80 years were eligible if they presented within 12 hours after the onset of STEMI that was indicated for primary PCI. Patients with uncontrolled congestive heart failure, history of malignancy, hematological disease, baseline creatinine level > 2.0 mg/dL, or dependence on dialysis were excluded. After angiographic assessment, the eligible patients who met all the inclusion criteria and none of the exclusion criteria, and/or their families, were asked for their informed consent by an independent coordinator. If they agreed to participate, the patients were randomly assigned to either the darbepoetin-α or the control group using a sealed envelope. Study protocol: All patients were treated in accordance with current practice guidelines for STEMI. Patients randomized to the darbepoetin-α group received bolus intracoronary darbepoetin-α (300 μg) directly into the ischemic myocardium using an over-the-wire balloon simultaneously with the first balloon inflation. The control group received the same volume of saline in the same manner. The dose of darbepoetin-α was chosen based on previous preclinical and clinical studies. [17] [18] [19] Thrombus aspiration or drug-eluting stent implantation was performed at the physician's discretion. TIMI flow grade and myocardial blush grade (MBG) were related with the prognosis of STEMI patients. 20, 21) Two interventional cardiologists who were blinded to the study reanalyzed coronary angiographic images and classified the TIMI flow and MBG as previously described. 20) ECGs were done on arrival emergency department (first ECG) and shortly after PCI (second ECG). The sum of ST-segment elevation was measured as described previously. 22) Complete resolution was defined as resolution of the sum of ST-segment elevation "70% on second ECG compared with first ECG, partial resolution as ST segment resolution < 70% to 30%, and no resolution as ST segment resolution < 30% to > 0%. Clinical follow-up was performed at 1, 2, and 4 months with 4 months follow-up CMR. Primary and secondary endpoints: The primary endpoint was myocardial infarct size, estimated based on cardiac biomarkers. We used the peak levels of creatine kinase-MB (CK-MB) and troponin-I (TnI). Cardiac biomarkers were monitored every 6 hours for 48 hours. The secondary endpoints were as follows: (1) infarct size, measured as the area of delayed enhancement observed on cardiac magnetic resonance (CMR) imaging after STEMI (baseline); (2) the proportion of salvaged myocardium at baseline, calculated using the following formula: (area at risk [AAR] − infarct size)/AAR × 100 (%); (3) the incidence of post-infarct remodeling, defined as an increase in the LV end-diastole volume of more than 20% at 4 months compared with baseline; and (4) the incidence of composite cardiovascular endpoints (cardiac death, nonfatal myocardial infarction, stent thrombosis, ischemic stroke, hospital readmission with heart failure or ischemic symptoms, bleeding, and target lesion revascularization) assessed during 4 months. The subgroup analysis according to total ischemic time (total ischemic time !3 hours versus > 3 hours) and region of infarction (anterior wall versus non-anterior wall STEMI) was performed for cardiac biomarkers and CMR results. Cardiac magnetic resonance imaging: The CMR studies were performed during the index admission (baseline) and at the 4-month follow-up using a 1.5-T MR system (Intera; Philips Medical Systems, Best, The Netherlands). Post-infarct remodeling involves several mechanisms and collagen deposition occurs up to 3 months. According, we performed 4-month follow-up CMR for confirming LV remodeling. 23, 24) All CMR images were acquired using electrocardiographic gating and breath holding. Images were analyzed with an off-line workstation (Extended MR Workspace 2.6; Philips Medical Systems, The Netherlands). Details of CMR data acquisition and analysis have been described previously.
16) The endocardial and epicardial contours were prescribed manually on the short-axis cine MR images of the LV at end-diastole and end-systole to estimate the LV end-diastole volume (EDV), LV endsystole volume (ESV), LV ejection fraction (EF), and LV mass. The AAR was determined as described previously. 25, 26) On the T2-weighted images, AAR was quantified as the region with a signal intensity of > 2 standard deviations greater than that obtained in the remote noninfarcted myocardium. If a central core region with a hypo-intense signal was present, that area was included in the AAR. Myocardial infarction was quantified by the delineation of hyper-enhancement on contrast-enhanced CMR. Microvascular obstruction was defined as an area of late hypo-enhancement within a hyper-enhanced region on late-enhancement images, and included in the calculation of total infarct size. The extent of AAR and myocardial infarction were expressed as absolute volumes. Sample size calculation: The peak CK-MB level of patients who underwent PCI with STEMI (< 12 hours) was 446.1 ± 228.3 ng/mL in a previous report, and another pilot study showed high-dose EPO administration in STEMI patients reduces 30% of CK-MB release. 8, 9) To detect a difference of 33% in the peak CK-MB level with 80% power and an α-error of 5% would require 36 patients in each study group. When the sample size is adjusted for an estimated 10% loss to follow-up, 40 patients are required in each group, making a total sample size of 80 patients. Statistical analysis: Categorical variables were presented as numbers and their percentages, and were analyzed using the χ 2 test. Continuous normally distributed variables were presented as mean ± standard deviation and were compared with Student t-test. Non-parametric continuous variables were presented as median values with interquartile ranges and were compared with Mann-Whitney U tests. The median values for each CMR parameter were compared at the baseline and 4-month by the Wilcoxon signed rank test in both group. The treatment effect of darbepoetin-α was defined as the difference in the mean value of the 4-month CMR result between the darbepoetin-α and control groups, and calculated using analysis of covariance (ANCOVA) adjusted for the baseline results. The Fisher's exact test was used to compare the incidence of the composite cardiovascular endpoints between the two groups.
All statistical analyses were performed using SPSS 24.0 for Windows (IBM Corp., Armonk, NY, USA), and a P value of < 0.05 was considered statistically significant.
Results
Study population and baseline characteristics:
Between November 2009 and May 2012, 80 patients with STEMI were randomized to either the darbepoetin-α or the control group (Figure 1 ). All the patients were assessed for cardiac biomarkers during hospitalization, and they completed the analysis of primary outcomes. During followup, 1 patient in the darbepoetin-α group withdrew informed consent, and 10 patients in the darbepoetin-α group and 5 patients in the control group refused to undergo baseline CMR. Finally, 26 patients in the darbepoetin-α group and 31 patients in the control group completed baseline and 4-month CMR. Cardiovascular endpoints were assessed in 79 patients during the 4 months of follow-up.
There were no significant differences in the baseline patient characteristics between the two groups (Table I) . Table II presents the periprocedural findings and medication after admission. Total ischemic time, from symptom onset to first balloon, was not different between the two groups. A total of 38 patients in the darbepoetin-α group and 40 patients in the control group were treated with a drug-eluting stent, and 2 patients in the darbepoetin-α group were treated with only thrombus aspiration because of no residual stenosis after aspiration. There were no significant differences in post-PCI blood pressure, TIMI flow grade, MBG, and ST-segment resolution between the two groups. One patient in the darbepoetin-α group and 3 patients in the control group were required short-term intraaortic balloon pump support. The medications prescribed after admission did not differ between the two groups. Myocardial infarct size estimated based on cardiac biomarkers: The peak levels of CK-MB and TnI after reperfusion did not significantly differ between the darbepoetin-α and control groups (Table III) . The peak levels of CK-MB and TnI were evaluated in subgroups classified according to total ischemic time (!3 hours versus > 3 hours) and region of infarction (anterior wall versus non-anterior wall STEMI), but no significant difference in any of the subgroups was observed. Cardiac magnetic resonance imaging results of infarct size and post-infarct remodeling: Baseline CMR was performed 20.4 ± 10.1 days after PCI in the darbepoetin-α group and 18.0 ± 9.5 days after PCI in the control group (P = 0.321). Four-month CMR was performed 126.0 ± 21.6 days after PCI in the darbepoetin-α group and 132.4 ± 19.4 days after PCI in the control group (P = 0.245). The myocardial infarct size was significantly decreased at the 4-month CMR compared with the baseline in both groups; however, there was no significant difference in interval change of infarct size between the two groups (P = 0.994) (Figure 2 ). at the 4-month follow-up. There were no significant differences in the baseline and 4-month CMR results between the two groups. The interval changes of EDV, ESV and EF during the 4 months was not significant in either group. Infarct size and AAR were significantly decreased in both groups at 4 months compared to the baseline. The treatment effect of darbepoetin-α did not have significant result in terms of any of the CMR parameters. The subgroup analysis according to total ischemic time (total ischemic time !3 hours versus > 3 hours) revealed no significant treatment effect of darbepoetin-α in any of the subgroup or in terms of CMR parameters (Figure 3) . The incidence of post-infarct LV remodeling did not significantly differ between the darbepoetin-α and control groups (8.0% versus 6.7%, P = 0.62). White blood cell counts, hemoglobin values, and platelet counts during hospitalization also did not differ between the two groups (Supplemental Figure) . Cardiovascular events developed in 5 patients in the darbepoetin-α group and in 3 patients in the control group, and there were no significant differences between the groups (Table V) .
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Discussion
In this randomized controlled trial, the intracoronary directly administration of darbepoetin-α into ischemic myocardium before reperfusion: (1) did not reduce the infarct size as estimated by peak cardiac biomarker levels in patients with STEMI; (2) did not reduce the infarct size or the proportion of salvaged myocardium on serial measurements of CMR imaging; and (3) did not reduce the incidence of post-infarct remodeling. The present study could not prove the efficacy of intracoronary darbepoetin-α during primary PCI in patients with STEMI.
EFFICACY OF INTRACORONARY DARBEPOETIN-α IN STEMI
Cardioprotective effects of erythropoietin in preclinical studies: Erythropoietin is produced by the fetal liver and adult kidneys and acts by stimulating the proliferation and survival of red blood cell (RBC) progenitors. 27) Although RBC progenitor cells are the major target of EPO, EPO receptors have been detected in tissues outside the blood, including the brain, heart, pancreas, gastrointestinal tract, and skeletal muscles. 28) These various presentations of EPO receptors suggest potential roles of EPO signaling beyond hematopoiesis. In preclinical studies, r-HuEPO protected against reperfusion injury and reduced infarct size in acute ischemic conditions. The main mechanism of the cardioprotective effects of r-HuEPO was accompanied by activation of the EPO receptor of the cardiomyocytecontrolled apoptotic signaling pathway. 5, 29) It was also shown to inhibit the reperfusion related myocardial inflammatory response independent from the anti-apoptotic signaling pathway. 6) Another considerable mechanism of rHuEPO was myocardial regeneration. EPO was a potent stimulant factor for the mobilization of endothelial progenitor cells and proliferation of endothelial cells, which were associated with new vascular formation in ischemic tissue. 7) Apoptotic signaling pathways related to reperfusion injury occur within the first few minutes, and neutrophil-induced inflammation occur within the first 6 hours and continues for 24 hours after reperfusion. 30, 31) Several preclinical studies have shown that there is a timing or dose dependent therapeutic window for reducing reperfusion injury. In a dog model, r-HuEPO was not effective in reducing the infarct size when EPO was injected 6 hours after ischemia. 32 ) In a rodent model for different time points for administration, high-dose r-HuEPO (3000 IU/Kg of epoetin) was effective from pre-ischemia up to 12 hours post-ischemia but not 24 hours, whereas lowdose r-HuEPO (150 IU/Kg) was effective only within 4 hours. 19) However, there was evidence that prolonged administration of r-HuEPO (beyond 24 hours after ischemia) has reduced infarct size through promoting neovascularization and mobilization of endothelial progenitor cells. 33) From these observations, it is presumed that the administration of high-dose r-HuEPO at the early stage of reperfusion and maintaining the therapeutic effect for more than 24 hours can be the most effective strategy for reducing reperfusion injury. Effect of intravenous administration of erythropoietin in clinical studies: Previous clinical studies evaluating the effects of intravenous administration of r-HuEPO on infarct size in patients with STEMI had conflicting results. In a small pilot study, high-dose r-HuEPO reduced infarct size as estimated by cardiac biomarkers and improved LV remodeling as assessed by CMR. 9) In the HEBE III trial, r-HuEPO treatment was associated with a smaller biomarker infarct size but this association was not significant. 10) However, other trials using intravenous r-HuEPO did not reduce either infarct size or LV remodeling. 8, 11, 12, 34, 35) Meta-analysis also did not show any beneficial effect of r-HuEPO in patients with STEMI. 36) The important limitations of clinical studies using intravenous r-HuEPO treatment were the timing and route of administration of r-HuEPO. In many randomized trials, administration of r-HuEPO was usually delayed until complete restoration of flow in the infarct-related artery. 10, 12, 34, 35) Reperfusion injury begins within a few minutes after restoration of flow in the culprit artery, and maintaining high-dose r-HuEPO in an ischemic myocardium at the time of reperfusion is an important factor in reducing reperfusion injury. Delayed administration of rHuEPO after reperfusion leads to the possibility of missing the effect on the acute phase apoptosis pathway. Some studies infused r-HuEPO intravenously before reperfusion, but intravenous administration could not guarantee satisfactory delivery of r-HuEPO to the ischemic myocardium because of coronary artery occlusion. 8, 11) The dose of rHuEPO is another important issue. Most preclinical studies used a high-dose (3,000-5,000 IU/kg) of r-HuEPO. To date, none of the randomized clinical studies directly compared low and high doses of r-HuEPO. However, a meta-analysis revealed that a higher dose of r-HuEPO (> 30,000 IU of epoetin-α) improved LVEF more significantly compared with the lower dose group (< 20,000 IU).
18) Accordingly, a high-dose of r-HuEPO may be more suitable for reducing reperfusion injury. Effect of intracoronary administration of erythropoietin in clinical studies: Intracoronary bolus administration of drugs results in higher concentration levels in the ischemic myocardium and local coronary bed.
15) The intracoronary administration of high-dose r-HuEPO at the time of coronary reperfusion may improve the local drug concentration and efficacy in the ischemic myocardium.
To overcome the limitations of previous studies, the present study was designed to maximize the efficacy of rHuEPO. We used a high-dose, long-acting EPO analog, 300 μg of darbepoetin-α, which corresponds to > 90,000 IU of epoetin-α. This enabled the therapeutic effect to be maintained beyond 24 hours after reperfusion. The darbepoetin-α was directly delivered into ischemic myocardium using an over-the-wire balloon simultaneously with first balloon inflation to achieve a high local drug concentration in the ischemic myocardium. Furthermore, this technique allowed darbepoetin-α to act during reperfusion occurred. Despite these specific efforts, darbepoetin-α did not reduce infarct size or post-infarct remodeling in patients with STEMI.
There were several factors for explaining the discrepancies of cardioprotective effect of r-HuEPO between preclinical and clinical studies. 37) Among them, the total ischemic time is an inevitable limitation of clinical studies. Most preclinical studies that demonstrated the efficacy of r-HuEPO had a total ischemic time within 1 hour. However, the mean ischemic time of clinical studies using r-HuEPO was over 3 hours. Although we tried to administer darbepoetin-α at the onset of reperfusion, the total ischemic time exceeded 3 hours. We performed subgroup analysis according to total ischemic time (!3 hours versus > 3 hours), but there were no significant differences in infarct size or post-infarct remodeling. However, most of the patients in the group with a total ischemic time !3 hours had over 2 hours of ischemic time, which did not allow comparison with preclinical studies.
Recently, Roubille, et al. reported that intracoronary administration of darbepoetin-α at the time reperfusion does not reduce infarct size in patients with STEMI.
38) The major difference from our study was the timing of intracoronary administration of darbepoetin-α. They administered darbepoetin-α immediately after re-opening of the culprit artery. In addition, they only evaluated the efficacy on infarct size. We tried to investigate not only infarct size but also post-infarct remodeling with serial measurements of CMR. Post-infarct remodeling continues for months until the distending forces are counterbalanced by the tensile strength of the scarred myocardium. 39) There is some preclinical evidence for EPO reducing post-infarct remodeling through anti-inflammatory and neo-angiogenesis in the early stages after infarction. 6, 7, 40) However, the present study could not prove the efficacy of intracoronary darbepoetin-α for reducing post-infarct remodeling in the clinical era. Safety of administration of erythropoietin: Although rHuEPO is generally well tolerated, it may be associated with adverse effects such as a thromboembolic effect. The safety of high-dose EPO therapy has been controversial. Two previous trials reported that high-dose r-HuEPO treatment was associated with an increasing risk of cardiovascular events. 12, 34) On the other hand, the HEBE III trial reported a lower incidence of adverse cardiovascular events in patients receiving high-dose r-HuEPO. 10) Other studies showed high-dose r-HuEPO was safe for shortand long-term cardiovascular outcomes in patients with STEMI. 41, 42) In the present study, composite cardiovascular events occurred in 5 patients in the darbepoetin-α group and in 3 patients in the control group. However, thromboembolic events occurred in 1 patient in the darbepoetin-α group, with 3 events in the control group. This result suggests that intracoronary administration of darbepoetin-α did not increase thrombotic complications in patients with STEMI. Study limitations: This study has several limitations. First, a relatively small number of patients were enrolled and about 30% of them refused CMR after enrollment. Second, due to the difficulty in enrollment, it took 3 years for the patient registration period. Third, to facilitate patient enrollment, STEMI patients within 12 hours were enrolled irrespective of the culprit vessel after protocol amendment. Although the culprit vessel was well balanced between the two groups, and subgroup analysis showed no significant interaction between the culprit vessel and the efficacy of darbepoetin-α, the heterogeneity of the culprit artery can be an important limitation of this study. Finally, the patients with STEMI included in this trial had better clinical outcomes than expected in general STEMI patients. Thus, it might be difficult to generalize the results of the present study to real world clinical practice.
Conclusion
Intracoronary administration of high-dose darbepoetin-α before reperfusion did not reduce infarct size or post-infarct LV remodeling in patients with STEMI.
